Macerich Schedules First Quarter 2025 Earnings Release and Conference Call SANTA MONICA, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- WHAT: Macerich (NYSE: MAC) Schedules First Quarter 2025 Earnings Release and Conference Call WHEN: Earnings Results will be released before market open on Monday, May 12, 2025. Management will hold a conference call at 10:00 am Pacific Time (1:00 pm Eastern Time) on that same day to discuss quarterly results. WHERE: Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dial-in num...
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study...
Revolution Medicines to Participate in April 2025 Investor Conferences REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in in two upcoming investor conferences. Details of the company’s participation are as follows: Needham 24th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. E...
Macerich and PenFed Credit Union Secure Exclusive Sponsorship Agreement for Tysons Corner Center Plaza Agreement Underscores PenFed Credit Union’s Long-Standing Commitment to the Local Community and its Members TYSONS, Va., March 20, 2025 (GLOBE NEWSWIRE) -- (NYSE: MAC), a leading owner, operator, and developer of major retail properties in top markets, has finalized terms with , America's second-largest federal credit union, on a new multi-year sponsorship and member engagement agreement. This exclusive deal enhances the branding power and reach of Tysons Corner Center’s experient...
A director at Macerich Co bought 7,000 shares at 16.400USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Macerich Advances HiFi, Outdoor Mixed-Use Development at FlatIron Crossing in Colorado, Names Entertainment Anchor Strategic Investment in Its Best Properties is Key Aspect of Macerich’s Path Forward Plan SANTA MONICA, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Macerich (NYSE: MAC), one of the nation’s leading owners, operators and developers of major retail properties in top markets, today announced that Pindustry will anchor HiFi, its mixed-use outdoor development project adjacent to premier retail destination FlatIron Crossing. HiFi at FlatIron Crossing...
Macerich Reports Fourth Quarter 2024 Results SANTA MONICA, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its Fourth Quarter 2024 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) today, Thursday, February 27, 2025, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive th...
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.